Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOTO-CAR (Monocyte-to-Macrophage CAR) is a proprietary in vivo cell therapy platform developed by Thunder Biotech. The technology utilizes nanoparticles to deliver genetic material encoding Chimeric Antigen Receptors (CARs) directly to monocytes and macrophages within the patient's body, bypassing the need for complex ex vivo manufacturing. Once engineered, these CAR-macrophages are designed to infiltrate solid tumors, recognize specific antigens (such as HER2 or Mesothelin), and stimulate a localized immune response while remodeling the immunosuppressive tumor microenvironment. The platform is being evaluated for the treatment of various solid tumors and inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MOTO-CAR.